Aerovate Therapeutics, Inc. (AVTE)
NASDAQ: AVTE · IEX Real-Time Price · USD
20.57
-1.34 (-6.12%)
May 17, 2024, 4:00 PM EDT - Market closed
Company Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States.
It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Aerovate Therapeutics, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jun 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 51 |
| CEO | Timothy P. Noyes M.B.A. |
Contact Details
Address: 930 Winter Street, Suite M-500 Waltham, Massachusetts 02451 United States | |
| Phone | 617-443-2400 |
| Website | aerovatetx.com |
Stock Details
| Ticker Symbol | AVTE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001798749 |
| CUSIP Number | 008064107 |
| ISIN Number | US0080641071 |
| Employer ID | 83-1377888 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Timothy P. Noyes M.B.A. | Chief Executive Officer and Director |
| George A. Eldridge | Chief Financial Officer and Treasurer |
| Dr. Marinus Verwijs Ph.D. | Chief Technical Officer |
| Dr. Benjamin T. Dake Ph.D. | Founder, President, Chief Operating Officer and Secretary |
| Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S | Chief Scientific Officer |
| Hunter Gillies M.D. | Chief Medical Officer |
| Timothy J. Pigot | Chief Commercial Officer |
| Donna Dea | Head of Regulatory Affairs |
| Susan Fischer | Executive Vice President of Development Operations |
| Stephen K. Yu | Senior Vice President of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 17, 2024 | 144 | Filing |
| May 16, 2024 | 144 | Filing |
| May 13, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |
| May 2, 2024 | 144 | Filing |
| May 1, 2024 | 144 | Filing |
| Apr 30, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |